Cerus Corp CERS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CERS is a good fit for your portfolio.
News
-
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
-
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
-
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
-
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
-
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results
-
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024
-
Cerus Corporation to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $1.70
- Day Range
- $1.66–1.79
- 52-Week Range
- $1.21–3.08
- Bid/Ask
- $1.74 / $1.75
- Market Cap
- $317.24 Mil
- Volume/Avg
- 429,491 / 1.7 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.06%
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 280
- Website
- https://www.cerus.com
Comparables
Valuation
Metric
|
CERS
|
TMDX
|
TELA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.85 | 20.60 | 5.93 |
Price/Sales | 1.96 | 11.64 | 1.79 |
Price/Cash Flow | — | 89.82 | — |
Price/Earnings
CERS
TMDX
TELA
Financial Strength
Metric
|
CERS
|
TMDX
|
TELA
|
---|---|---|---|
Quick Ratio | 1.50 | 8.34 | 3.33 |
Current Ratio | 2.14 | 9.30 | 4.23 |
Interest Coverage | −3.45 | −2.63 | −7.93 |
Quick Ratio
CERS
TMDX
TELA
Profitability
Metric
|
CERS
|
TMDX
|
TELA
|
---|---|---|---|
Return on Assets (Normalized) | −8.70% | −1.28% | −54.30% |
Return on Equity (Normalized) | −32.26% | −4.30% | −196.29% |
Return on Invested Capital (Normalized) | −7.65% | −1.70% | −59.27% |
Return on Assets
CERS
TMDX
TELA
Medical Devices Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
ABT
| Abbott Laboratories | Hlrzzzbk | Pxpbsnr | $185.8 Bil | |
SYK
| Stryker Corp | Mqkphnstx | Mqnv | $124.7 Bil | |
MDT
| Medtronic PLC | Jsjszdz | Dsdxgx | $105.2 Bil | |
BSX
| Boston Scientific Corp | Yksnvqbkp | Gstgt | $99.0 Bil | |
EW
| Edwards Lifesciences Corp | Qjcmhnln | Mlbxnt | $52.3 Bil | |
DXCM
| DexCom Inc | Nytcypsfw | Gjhh | $52.1 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Dmylndqglf | Jpmy | $24.8 Bil | |
ALGN
| Align Technology Inc | Gcjrqqvz | Wvvpld | $22.6 Bil | |
PHG
| Koninklijke Philips NV ADR | Sqvxkgp | Mmdcng | $18.5 Bil | |
PODD
| Insulet Corp | Ymxmwzkk | Qswlnb | $11.5 Bil |